Investor Relations
Jul 16, 2018
OPKO Partner Vifor Fresenius Receives Marketing Approval for RAYALDEE in Canada MORE >>
Jun 11, 2018
OPKO Health Completes Enrollment in Phase 2b Study of OPK88003 to Treat Type 2 Diabetes and Obesity MORE >>
May 18, 2018
OPKO Plans to Address Draft Local Coverage Determination Published by Novitas Solutions for 4Kscore Test MORE >>
May 08, 2018
OPKO Health Reports First Quarter 2018 Financial Results MORE >>

Press Releases

All Releases
OPKO Health's GeneDx Announces Participation in Illumina's iHope Program on International Rare Disease Day
Feb 28, 2017
MIAMI , Feb. 28, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), today announces that GeneDx, a subsidiary of OPKO Health , is proud to participate as a founding member in Illumina Inc.'s (NASDAQ:ILMN) iHope Network on International Rare Disease Day, which takes place today.
OPKO Health to Announce 2016 Fourth Quarter Financial Results on March 1, 2017
Feb 27, 2017
MIAMI , Feb. 27, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), a multinational biopharmaceutical and diagnostics company, will announce operating and financial results for the fourth quarter ended December 31, 2016 after the close of the U.S.
OPKO Health to Participate at Upcoming Healthcare Investment Conferences
Feb 21, 2017
MIAMI , Feb. 21, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced that senior management will participate at the 2017 RBC Capital Markets' Healthcare Conference taking place February 22-23, 2017 at the New York Palace Hotel and at the Cowen Group's 37 th Annual Health Care
OPKO Spain to Start Trial of Once-A-Year Intra-Articular Injectable for Osteoarthritis
Feb 08, 2017
MIAMI , Feb. 08, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced that its wholly owned subsidiary, OPKO Health Spain, has completed development of Enko 1, a patented intra-articular injectable hyaluronic acid and chondroitin sulfate complex to relieve pain and improve
OPKO Health Promotes Thomas Nusbickel to Renal Division Chief Commercial Officer
Feb 07, 2017
Enhances leadership for RAYALDEE ® with deep industry knowledge in nephrology; refocuses commercial structure on field representatives MIAMI , Feb. 07, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) announced the promotion of Thomas Nusbickel to the newly created position of Chief
OPKO'S GeneDx Announces Research Collaboration with the Wellcome Trust Sanger Institute
Feb 01, 2017
MIAMI , Feb. 01, 2017 (GLOBE NEWSWIRE) -- (Nasdaq:OPK) OPKO Health, Inc. announced today that its subsidiary and business unit, GeneDx, is entering into a collaboration with the Deciphering Developmental Disorder (DDD) study led by the Wellcome Trust Sanger Institute .  The Wellcome Trust Sanger
OPKO Investee Zebra Biologics Announces Collaboration with AbbVie to Discover New Antibody Therapeutics
Jan 10, 2017
MIAMI , Jan. 10, 2017 (GLOBE NEWSWIRE) -- (Nasdaq:OPK) —OPKO Investee, Zebra Biologics Inc. , an emerging biotechnology company of which OPKO owns approximately 28%, announced it has entered into a collaboration with AbbVie to discover agonist antibody therapeutics for inflammatory diseases.
OPKO Announces Initiation of Claros® 1 Clinical Trial for Total PSA
Jan 09, 2017
MIAMI , Jan. 09, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced the initiation of a multi-center clinical validation study for the Company's proprietary Total PSA microfluidic assay cassette running on the Claros ® 1 in-office immunoassay analyzer.
OPKO Health to Present at the J.P. Morgan 35th Annual Healthcare Conference
Jan 04, 2017
MIAMI , Jan. 04, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced that senior management will present at the J.P. Morgan 35 th Annual Healthcare Conference on Wednesday, January 11, 2017 at 9:00 AM (PT) . The presentation will be webcast on the OPKO Investor Relations page of
OPKO Health Provides Update on hGH-CTP Clinical Programs
Dec 30, 2016
Commenced data analysis of the Phase 3 Clinical Study of hGH-CTP in Growth Hormone Deficient Adults   Initiated Global Pediatric Phase 3 Clinical Study of hGH-CTP in Growth Hormone Deficient Children MIAMI , Dec. 30, 2016 (GLOBE NEWSWIRE) -- OPKO Health, Inc.
OPKO Health to be Added to the NASDAQ Biotechnology Index
Dec 19, 2016
MIAMI , Dec. 19, 2016 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) announces that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI) effective as of the opening of trading on Monday, December 19, 2016. The NASDAQ Biotechnology Index is designed to track the
OPKO Health to Participate at Three Investment Conferences in December
Nov 30, 2016
MIAMI , Nov. 30, 2016 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), announces that its senior management team will host one-on-one investor meetings with institutional investors participating at the following investor conferences in December: Evercore ISI MedTools Investor Conference taking
OPKO Announces U.S. Launch of RAYALDEE™
Nov 23, 2016
MIAMI , Nov. 23, 2016 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq:OPK), today announced that it will commence shipments of RAYALDEE™ (calcifediol) extended-release capsules to distributors in the United States on Tuesday, November 29, 2016 .  The product will be available nationwide at retail
OPKO Presents Data on RAYALDEE® at ASN Kidney Week 2016
Nov 17, 2016
MIAMI , Nov. 17, 2016 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq:OPK), announced that data on RAYALDEE (calcifediol) extended-release capsules as a treatment for secondary hyperparathyroidism (SHPT) in stage 3 and 4 chronic kidney disease patients with vitamin D insufficiency will be presented
OPKO Health Reports Third Quarter Financial and Operating Results
Nov 07, 2016
Consolidated revenue increased to $298.0 million for the three months ended September 30, 2016 from $143.0 million for the comparable period of 2015.  Consolidated revenue for the nine months ended September 30, 2016 increased to $946.2 million from $215.5 million for the comparable period of 2015.
OPKO to Announce Third Quarter Operating and Financial Results on November 7, 2016
Nov 03, 2016
MIAMI , Nov. 03, 2016 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) will release operating and financial results for the three months ended September 30, 2016 , after the close of the U.S. financial markets on Monday, November 7, 2016 .  OPKO's senior management will provide a business update
OPKO Health Enters Companion Animal Health Market
Oct 27, 2016
MIAMI , Oct. 27, 2016 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) announced today its entry into the animal health market.  The OPKO animal health team will operate as a specialty business unit in cooperation with OPKO Spain, which is already in this business, and OPKO Ireland , which has
OPKO Health Appoints Dr. Benjamin Solomon as Managing Director of GeneDx
Sep 27, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NASDAQ:OPK) , announces the appointment of Benjamin D. Solomon , M.D. as Managing Director of GeneDx, effective as of October 3, 2016 . GeneDx, part of OPKO's BioReference Laboratories subsidiary, specializes in genetic testing for rare hereditary
OPKO Health to Present at the Ladenburg Thalmann 2016 Healthcare Conference
Sep 19, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (NASDAQ:OPK) today announced that senior management will present at the Ladenburg Thalmann 2016 Healthcare Conference on September 27th, 2016 at 10:30 AM (ET) . About OPKO Health OPKO Health, Inc. is a diversified healthcare company that seeks to
OPKO Health Appoints Jane Pine Wood as Chief Legal and Compliance Officer of BioReference Laboratories
Sep 13, 2016
MIAMI --(BUSINESS WIRE)-- OPKO Health, Inc. (Nasdaq: OPK) announces the appointment of Jane Pine Wood , Esq. as Chief Legal and Compliance Officer of its wholly owned subsidiary, BioReference Laboratories , effective October 1, 2016 . Ms. Wood is a nationally respected healthcare attorney who has
Displaying 41 - 60 of 355